Sandbox Reserved 430: Difference between revisions

Line 40:

Acute coronary syndrome, a condition in which there is sudden blockage of blood flow to the heart, is majorly caused by a disease known as atherothrombosis. This disease is characterized by blocked arteries due to thrombosis: formation of a clot within a blood vessel. The P2Y12 protein is an important platelet receptor inhibitor that can be combined with aspirin in the management of ACS. It regulates certain functions through purinergic signaling, which is a form of extracellular signaling mediated by purine nucleotides and nucleosides like ADP and ATP.

The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, a seven-transmembrane domain protein linked to the cAMP-signaling pathway. It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.

The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, <scene name='48/483887/Sun/1'>a seven-transmembrane domain protein</scene> linked to the cAMP-signaling pathway. It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.

Clopidogrel is a pro-drug and thienopyridine-type inhibitor of the P2Y12 receptor, which requires Cytochrome P450 to hepatically transform it to exert its anti platelet effect. <scene name='48/483887/P450/1'>Click Here</scene> to see this interaction between the P450 complex and Clopidogrel.

Sandbox Reserved 430: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 40: / Line 40: @@
 Acute coronary syndrome, a condition in which there is sudden blockage of blood flow to the heart, is majorly caused by a disease known as atherothrombosis. This disease is characterized by blocked arteries due to thrombosis: formation of a clot within a blood vessel. The P2Y12 protein is an important platelet receptor inhibitor that can be combined with aspirin in the management of ACS. It regulates certain functions through purinergic signaling, which is a form of extracellular signaling mediated by purine nucleotides and nucleosides like ADP and ATP.
-The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, a seven-transmembrane domain protein linked to the cAMP-signaling pathway.  It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.
+The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, <scene name='48/483887/Sun/1'>a seven-transmembrane domain protein</scene>  linked to the cAMP-signaling pathway.  It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.
 Clopidogrel is a pro-drug and thienopyridine-type inhibitor of the P2Y12 receptor, which requires Cytochrome P450 to hepatically transform it to exert its anti platelet effect. <scene name='48/483887/P450/1'>Click Here</scene> to see this interaction between the P450 complex and Clopidogrel.